

Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis

MB Garg^{1,2}, LF Lincz^{2,3,4}, K Adler¹, FE Scorgie^{2,3}, SP Ackland^{1,2,4} and JA Sakoff^{*,1,2,4}

¹Department of Medical Oncology, Calvary Mater Newcastle Hospital, Hunter Regional Mail Centre, Locked Bag No 7, Waratah, NSW 2310, Australia;

²Hunter Medical Research Institute (HMRI) Cancer Research Program, Newcastle, NSW, Australia; ³Hunter Haematology Research Group, Calvary Mater Newcastle Hospital, Waratah, NSW, Australia; ⁴The University of Newcastle, Callaghan, NSW, Australia

BACKGROUND: Identifying various pretreatment factors that predict chemotherapy-induced toxicity in colorectal cancer (CRC) patients undergoing treatment for their disease is crucial to optimising patient care.

METHODS: Seventy-three patients received adjuvant 5-fluorouracil (5FU)/leucovorin using either the Mayo Clinic ($n = 42$) or a weekly schedule ($n = 31$) and evaluated for clinical toxicity. Pretreatment blood analysis included measures of plasma uracil and dihydrouracil, peripheral blood mononuclear cell (PBMNC) telomere length (TL), standard biochemistry and cell differential analysis. On the first day of treatment 5FU-pharmacokinetic variables of area under the curve, half life and clearance were also measured. These variables together with age and gender were used in univariate and multivariate analysis as predictors of clinical toxicity.

RESULTS: For the Mayo schedule the primary toxicities were neutropenia (69%), mucositis (58%) and leukopenia (46%), with 70% of patients presenting with haematological toxicity \geq grade 1 (neutropenia and/or leukopenia). Multivariate analysis showed that haematological toxicity was predicted by short TL, high platelet lymphocyte ratio (PLR) and low neutrophil count ($R^2 = 0.38$, $P < 0.0006$), whereas mucositis was predicted by age, TL and PLR ($R^2 = 0.34$, $P < 0.001$). For the weekly schedule diarrhoea predominated (16%), with female gender as the only predictive factor. Although measures of uracil metabolism correlated well with 5FU metabolism ($r = 0.45$ – 0.49), they did not indicate abnormal pyrimidine metabolism in this cohort and not surprisingly failed to predict for 5FU toxicity.

CONCLUSION: Short TL of PBMNC and an increased PLR were strong predictors of mucositis and haematological toxicity in CRC patients undergoing 5FU treatment in the adjuvant setting.

British Journal of Cancer (2012) 107, 1525–1533. doi:10.1038/bjc.2012.421 www.bjcancer.com

Published online 18 September 2012

© 2012 Cancer Research UK

Keywords: pharmacokinetics; telomere length; 5FU toxicity; platelet lymphocyte ratio; colorectal cancer

Defining the parameters contributing to clinical toxicity has been the subject of study by our group for several years (Gurney *et al*, 1998; Garg *et al*, 2002). Although some of the variability in toxicity is accounted for by variations in drug pharmacokinetics (PK), differences in co-morbidity (cardiac, liver or renal diseases), and predisposing factors (gender and age), a considerable proportion remains unexplained. 5-Fluorouracil (5FU) has been used as standard chemotherapy for the adjuvant treatment of colorectal cancer (CRC) for more than 50 years. Similar to many other antineoplastic agents, 5FU has a relatively narrow therapeutic window and wide inter-patient variability in toxicity. The traditional practice of normalising dose to body surface area (BSA) takes into account only two variables (height and weight). Not surprisingly, patients experience a wide range of toxicities and severities, with the primary dose-limiting complications being neutropenia, leukopenia, mucositis and diarrhoea (Tsalcic *et al*, 2003; Patel *et al*, 2004). There is clearly a need for better pretreatment markers that can predict for 5FU-induced toxicity in CRC patients well in advance of their chemotherapy.

Various studies have examined 5FU PK in CRC patients and shown significant variability in 5FU area under the curve (AUC) and clearance (Cl) of up to three-fold (Goldberg *et al*, 1988; Milano *et al*, 1994; Vokes *et al*, 1996; Gusella *et al*, 2009). Approximately 80% of 5FU is cleared by catabolism via dihydropyrimidine dehydrogenase (DPD) (Sommadossi *et al*, 1982). Variability in DPD activity can occur due to physiologic factors, organ dysfunction and genetic polymorphisms. Complete or partial familial deficiencies have also been reported (Diasio *et al*, 1988; Lu *et al*, 1993; Etienne *et al*, 1994; Van Kuilenburg *et al*, 1999). A simple marker for catabolism of 5FU and thus DPD activity before therapeutic dosing is the analysis of endogenous pyrimidine levels. As DPD catalyses the production of dihydrouracil (UH₂) and dihydrofluorouracil (FUH₂) from uracil (U) and 5FU, respectively, analysis of the endogenous UH₂/U ratio has been proposed to predict 5FU catabolism and thus toxicity (Gamelin *et al*, 1999; Ciccolini *et al*, 2006).

Predicting the effect of 5FU on normal tissue, particularly of haematological origin, is important in identifying those patients most likely to experience toxicity. In this regard, our research efforts have turned towards defining the replicative capacity of bone marrow progenitors cells (Lincz *et al*, 2004). We have shown that the ability of stem cells to repopulate the haematopoietic system after myeloablation is dependent upon stem cell telomere length (TL) (Lincz *et al*, 2004). Telomeres are tandemly repeated

*Correspondence: Dr JA Sakoff; E-mail: jennette.sakoff@newcastle.edu.au
Received 1 May 2012; revised 20 August 2012; accepted 29 August 2012; published online 18 September 2012

hexanucleotide sequences (TTAGGG) located at the ends of linear chromosomes, which progressively become shorter with time leading to cell senescence (Rhyu, 1995; Blackburn, 2005). We have previously shown that TL of peripheral blood mononuclear cell (PBMNC) accurately reflects TL of bone marrow cells (Sakoff *et al*, 2002). We propose that TL of PBMNC is a marker of bone marrow replicative capacity and thus a predictor for 5FU-induced haematopoietic toxicity.

Baseline blood parameters of neutrophil to lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR), well-known markers of systemic inflammatory response (SIR), have already been shown to be useful prognostic indicators for cancer patients. The NLR has been shown to predict for clinical benefit, progression and survival in CRC patients with metastatic disease (Chua *et al*, 2011a), whereas the PLR has been shown to predict for blood toxicity in patients with non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy (Arrieta *et al*, 2010).

The aim of this study was to conduct a comprehensive survey of clinically measurable variables in order to determine the best predictors of 5FU toxicity. Although many of these variables have been investigated in separate studies (Chua *et al*, 2011b), few have analysed all of them in a single cohort. The present study also incorporates a unique set of biomarkers including measures of uracil catabolism, TL and SIRs, which have not previously been examined in relation to chemotherapy-induced toxicity in CRC patients.

MATERIALS AND METHODS

Patient cohort

Eligible patients had a recent diagnosis of CRC stage B or C, and were of any age, both genders, with ECOG performance status 0, no other significant medical illness and normal haematological (Hb > 100 g l⁻¹, white blood count (WBC) > 4.0 × 10⁹ per l, platelets > 100 × 10⁹ per l), liver (bilirubin < ULN (upper limit normal), ALT < 2 × ULN, ALP < 2 × ULN) and renal function (creatinine > 130 mmol l⁻¹). Written informed consent was obtained from all participants and the research was approved by the Hunter Area Health Research Ethics Committee. Patient recruitment was between year 2001–2004. Patients were given 5FU and folinic acid (leucovorin, LV) for 6 months by either the Mayo Clinic schedule (5FU 425 mg m⁻² and LV 20 mg m⁻² daily for 5 days every 4 weeks) or a weekly schedule (5FU 500 mg m⁻² and LV 20 mg m⁻² weekly for 4 weeks). 5-Fluorouracil was given over 5–10 min after a bolus of LV.

Blood samples

Baseline blood samples were collected on the day (time range 8:45–16:00 hours) before 5FU/LV administration, for measurement of PBMNC TL (EDTA, 4 ml), U and UH₂ (lithium heparin, 5 ml). Post-treatment blood samples were collected at 10 min, 30 min, 45 min and 60 min after 5FU administration, for measures of 5FU and FUH₂ (lithium heparin, 5 ml). Blood was also collected before treatment and at the end of the first month for blood biochemistry analysis, and twice weekly for the first month for a complete blood count and differential using Hunter Area Pathology Service, NSW, Australia. Non-treated blood plasma samples were purchased from the Red Cross and used as controls and standards for the high-performance liquid chromatography (HPLC) assays.

Clinical toxicity

Patients were evaluated clinically for toxicity before starting chemotherapy and weekly during the first month. Clinical toxicity data was categorised by using Standard NCI CTC ver.2.0 criteria and included four gradings for each of thrombocytopenia, leukopenia, neutropenia, febrile neutropenia, mucositis and

diarrhoea. Haematological toxicity (≥ grade 1) was defined as the existence of at least one toxicity of grade 1 or greater in the categories of leukopenia or neutropenia. A complete blood count and differential was performed twice weekly for the first month. Electrolytes, urea, creatinine and liver function tests (bilirubin, AST, ALT, Albumin, LDH) were performed before treatment and at the end of the first month.

5-Fluorouracil pharmacokinetics

Plasma from the baseline blood sample and 10 min, 30 min, 45 min and 60 min after the first infusion of 5FU/LV, was analysed for 5FU and FUH₂ concentration by HPLC with variable UV detection using our previously published method (Ackland *et al*, 1997). Plasma standards in the concentration range of 0.20–20 μmole l⁻¹, were prepared by adding aqueous stock standards to pooled human plasma. The concentration of 5FU and FUH₂ in patient samples and quality control samples was determined from the calibration curves. Plasma 5FU and FUH₂ concentration values at four time points after the first dose were used to calculate various PK variables including the area under the time/concentration curve (AUC), total body Cl and terminal half life (T_{1/2}) using a non-compartmental model, WinNonlin (v 5.0). All blood samples were processed within 10 min of venipuncture. We have previously shown no degradation of 5FU using this methodology (Ackland *et al*, 1997).

Uracil catabolism

Plasma from the baseline blood sample was analysed for U and UH₂ concentration by HPLC with variable UV detection using our previously published method (Garg *et al*, 2002). Plasma standards in the concentration range of 0.02–5.0 μmole l⁻¹, were prepared by adding aqueous stock standards to double-dialysed (U and UH₂-free) pooled human plasma. The concentration of U and UH₂ in patient samples and quality control samples was determined from the calibration curves.

Telomere length

Measures of PBMNC TL were used to predict bone marrow replicative capacity (Sakoff *et al*, 2002). Peripheral blood mononuclear cells were separated from fresh whole blood, genomic DNA was extracted using the mini salt extraction method (Miller *et al*, 1988) and analysed for TL by our previously described method (Sakoff *et al*, 2002) involving DNA enzymatic digestion and Southern blotting. For each sample, the average of two mean TLs calculated from two separate blots was used for statistical analysis.

Statistical analysis

Data collected included demographic, clinical toxicity, complete blood count and differential, biochemistry panel, 5FU PK variables, measures of plasma U and UH₂, and TL analysis. All data that failed normality was appropriately transformed (log or sqrt) before statistical analysis. All toxicity data was categorised by standard NCI CTC ver.2.0 criteria and treated as ordinal categorical or binomial variables as indicated. Differences between cohorts were determined by student's *t*-test and linear correlations were assessed by Pearson correlation coefficient, univariate analysis was performed by linear regression and only variables with *P*-values < 0.25 were included in subsequent multivariate models. For multivariate analysis, backward stepwise regression with casewise deletion was used to determine those variables significantly contributing to each of the respective toxicity outcomes. Statistica (StatSoft, Tulsa, OK, USA) v 6.0 programme was used for statistical analysis. *P*-values < 0.05 were considered statistically significant.

RESULTS

Baseline characteristics

Seventy-three CRC patients (median age 63 years; range 34–82 years; 42 males; 31 females; 11 stage B, 62 stage C) received adjuvant 5FU/LV with either the Mayo Clinic schedule ($n=42$) or weekly schedule ($n=31$) according to clinician preference (Table 1). The two groups showed a similar age and gender distribution. There were no differences between the two patient cohorts in terms of BSA, AST, albumin, bilirubin and creatinine. No underlying clinical predisposition in terms of liver and renal function was identified in either group. Baseline WBC, absolute neutrophil count (ANC) and platelets were within normal limits

Table 1 Patient characteristics and toxicity by 5FU treatment regimen

	Treatment regimen	
	Mayo daily schedule $n=42$	Weekly schedule $n=31$
5FU (mg m^{-2})	425	500
LV (mg m^{-2})	20	20
Schedule	Daily for 5 days every 4 weeks	Weekly for 4 weeks
Gender, n (%)		
Male	24 (57)	18 (58)
Female	18 (43)	13 (42)
Age (years)	62 (58–66)	64 (54–72)
CRC, n (%)		
Stage B	5 (12)	6 (19)
Stage C	37 (88)	25 (81)
Platelet nadir (10^9 l^{-1})	231 (196–269)	236 (215–258)
WBC nadir (10^9 l^{-1})	3.7 (2.6–4.7)	4.8 (4.1–6.4)
ANC nadir (10^9 l^{-1})	0.7 (0.3–2.0)	2.6 (1.7–3.7)
Thrombocytopenia, n (%)		
Grade 4	1 (2)	0 (0)
Leukopenia, n (%)		
Grade 1	4 (10)	3 (10)
Grade 2	11 (27)	1 (3)
Grade 3	3 (7)	1 (3)
Grade 4	1 (2)	0 (0)
Neutropenia, n (%)		
Grade 1	2 (5)	6 (19)
Grade 2	5 (12)	2 (6)
Grade 3	8 (20)	1 (3)
Grade 4	13 (32)	0 (0)
Haematological toxicity \geq Grade I	29 (70)	10 (32)
Febrile neutropenia, n (%)		
Grade 3	1 (2)	1 (3)
Grade 4	2 (5)	0 (0)
Mucositis, n (%)		
Grade 1	4 (10)	2 (6)
Grade 2	15 (36)	2 (6)
Grade 3	5 (12)	0 (0)
Diarrhoea, n (%)		
Grade 1	17 (40)	8 (26)
Grade 2	3 (7)	3 (10)
Grade 3	2 (5)	2 (6)

Abbreviations: 5FU = 5-Fluorouracil; ANC = absolute neutrophil count; CRC = colorectal cancer; LV = leucovorin; WBC = white blood count. Values for non categorical data are median (lower–upper quartile).

with no differences between the patient populations. No differences were observed in NLR and PLR between the two cohorts. The number of patients with $\text{NLR} \geq 5$ was 4 out of 42 and 2 out of 31, whereas 18 out of 42 and 13 out of 31 patients presented with $\text{PLR} \geq 150$ in the Mayo and weekly cohorts, respectively. Telomere length (median) was slightly longer in the Mayo population of patients than in weekly patients although not statistically significant (Table 2).

Clinical toxicities

The overall clinical toxicity was greater in the Mayo daily schedule compared with the weekly schedule, but with differences in type of side-effect. The primary toxicities (\geq grade 2) for the Mayo schedule were neutropenia (26 (63%)), mucositis (20 (48%)) and leukopenia (15 (37%)), whereas the predominant toxicity (\geq grade 2) for the weekly schedule was diarrhoea (5 (16%)). Indeed, 70% of patients receiving the Mayo schedule presented with grade 1 or greater haematological toxicity (leukopenia and/or neutropenia) compared with 32% of patients receiving the weekly schedule. Following treatment, 21 patients on the Mayo schedule had an ANC nadir $<1 \times 10^9$ per l, while only one patient observed ANC nadir $<1 \times 10^9$ per l with the weekly schedule. A total of seven patients were admitted to hospital for management of toxicity (one with isolated neutropenic fever/sepsis, two with neutropenia and mucositis, two with neutropenia and diarrhoea, one with diarrhoea and mucositis and one with isolated diarrhoea).

5-Fluorouracil pharmacokinetics and endogenous pyrimidine catabolism

5-Fluorouracil pharmacokinetic data after the first dose of 5FU including 5FU AUC ($\mu\text{mole l}^{-1} \text{ h}^{-1}$), 5FU Cl ($\text{l}^{-1} \text{ h}^{-1}$), terminal half life $T_{1/2}$ (h), and AUC values for its metabolite FUH₂, are detailed in Table 2 for each treatment schedule together with various baseline blood parameters. The 5FU AUC was significantly lower for the Mayo schedule than the weekly schedule primarily as a consequence of a lower administrated dose (425 vs 500 mg) (Table 2). The Mayo schedule showed a shorter half life (0.16 vs 0.20), a greater Cl (148 vs 105) and a higher 5FUH₂ AUC (32 vs 24) than the weekly schedule, indicating greater catabolism efficiency; however, these differences were not statistically significant.

In an effort to predict for 5FU catabolism, endogenous pyrimidine catabolism was examined for each treatment schedule via measurements of U and UH₂. No significant differences were observed between the patient cohorts. Comparisons between 5FU catabolic parameters (5FU $T_{1/2}$, 5FU Cl and 5FUH₂ AUC) and uracil catabolic parameters (UH₂ and UH₂/U) (see Table 3) showed that UH₂ significantly correlated and predicted for 5FUH₂ AUC using either the Mayo or weekly schedule. The ratio of UH₂/U also significantly predicted for 5FUH₂ AUC for the Mayo schedule and predicted for 5FU $T_{1/2}$ for the weekly schedule.

Univariate analysis

Univariate analysis was performed for all grades of leukopenia and neutropenia, as well as overall haematological toxicity (\geq grade 1) and mucositis for the Mayo schedule and diarrhoea for the weekly schedule as these were the primary toxicities for each treatment regimen. The pharmacokinetic and pharmacodynamic variables used in the analysis and the correlation statistics are shown in Table 4. Leukopenia and neutropenia significantly correlated with the pharmacokinetic parameters, BSA, 5FU AUC, 5FU $T_{1/2}$ and 5FU Cl, thus the greater the 5FU exposure the greater the toxicity. Moreover, leukopenia and neutropenia inversely correlated with PBMNC TL. A significant association was also observed between the induction of leukopenia and increased baseline platelet and decreased lymphocyte counts. This in turn produced a significant

Table 2 PK and PD parameters by 5FU treatment regimen

	Treatment regimen			
	Mayo daily schedule		Weekly schedule	
	n		n	
<i>Pharmacokinetics</i>				
BSA (m ²)	42	1.92 (1.76–2.05)	31	1.93 (1.73–2.10)
5FU AUC (μmol l ⁻¹ h ⁻¹)	39	41 (31–49)	28	62 (46–84)*
5FU T _{1/2} (h)	39	0.16 (0.14–0.20)	28	0.20 (0.15–0.26)
5FU Cl (l h ⁻¹)	39	148 (107–202)	28	105 (70–160)
5FUH ₂ AUC (μmol l ⁻¹ h ⁻¹)	39	32 (19–41)	28	24 (16–38)
U (μmole l ⁻¹)	39	0.13 (0.08–0.16)	29	0.11 (0.08–0.16)
UH ₂ (μmole l ⁻¹)	38	1.30 (0.75–1.86)	29	0.97 (0.62–1.45)
UH ₂ /U	38	10.6 (6.6–15.7)	29	9.5 (5.1–13.1)
AST (U l ⁻¹)	41	22 (17–25)	29	21 (18–29)
Albumin (g l ⁻¹)	42	37 (35–39)	29	38 (34–40)
Bilirubin (μmol l ⁻¹)	42	11 (7–14)	29	10 (8–13)
Creatinine (mmol l ⁻¹)	42	75 (66–86)	30	80 (68–89)
<i>Pharmacodynamics</i>				
WBC × (10 ⁹ l ⁻¹)	42	7.80 (6.5–8.9)	31	7.3 (5.9–8.8)
Platelet × (10 ⁹ l ⁻¹)	42	282 (261–361)	31	283 (254–323)
ANC × (10 ⁹ l ⁻¹)	42	5.0 (3.9–5.5)	31	4.3 (3.2–6.0)
Lymphocyte × (10 ⁹ l ⁻¹)	42	1.95 (1.6–2.3)	31	1.9 (1.3–2.5)
NLR	42	2.35 (1.8–3.1)	31	2.26 (1.6–3.3)
PLR	42	147 (124–186)	31	134 (110–215)
Telomere length (kb)	34	9.91 (7.32–13.61)	29	8.36 (6.52–9.66)

Abbreviations: 5FU = 5-fluorouracil; ANC = absolute neutrophil count; AUC = area under the curve; BSA = body surface area; FUH₂ = dihydrofluorouracil; NLR = neutrophil to lymphocyte ratio; PD = pharmacodynamics; PK = pharmacokinetics; PLR = platelet lymphocyte ratio; U = uracil; UH₂ = dihydrouracil; WBC = white blood count. Values for non categorical data are median (lower–upper quartile). *Significantly different between Mayo and weekly schedule $P < 0.01$.

Table 3 Correlation (r) between uracil catabolism and 5FU catabolism by 5FU treatment regimen

	Treatment regimen			
	Mayo daily schedule		Weekly schedule	
	n = 38		n = 27	
	UH ₂	UH ₂ /U	UH ₂	UH ₂ /U
5FU T _{1/2}	–0.164	–0.098	–0.206	–0.381*
5FU Cl	0.201	–0.045	0.023	0.101
5FUH ₂ AUC	0.493**	0.449**	0.481**	0.153

Abbreviations: 5FU = 5-fluorouracil; AUC = area under the curve; FUH₂ = dihydrofluorouracil; U = uracil; UH₂ = dihydrouracil. * $P < 0.05$, ** $P < 0.01$.

positive association with leukopenia and PLR. Haematological toxicity (\geq grade 1) was significantly associated with 5FU AUC, 5FU T_{1/2}, 5FU Cl, moreover, the baseline variables of WBC, ANC and TL also showed significant associations. The presence of mucositis in this patient cohort significantly correlated with younger age and an increase in PLR. The primary toxicity induced by the weekly schedule of 5FU treatment was diarrhoea and this was only associated with gender, with females presenting with greater toxicity than males in this cohort.

Collectively, the pretreatment variables BSA, PLR, age, WBC, ANC and TL at baseline were associated with increased toxicity in the Mayo cohort of patients. The strongest association for these parameters and toxicity in this cohort are shown in Figure 1. The data clearly show that a low BSA and a high PLR is associated with increased toxicity (leukopenia data shown), whereas young

patients particularly those under the age of 52 ($n = 4$) presented with high-grade mucositis (\geq grade 2). Furthermore, a baseline WBC, ANC and TL less than the median for the population significantly is associated with an increased incidence of haematological toxicity. Indeed, 95% of patients with a TL less than the median (9525 bp, $n = 33$) presented with haematological toxicity (\geq grade 1) equating to a 14-fold increased odds (95% CI: 1.3–669, $P = 0.013$). In order to gauge the magnitude of these effects on high grades of haematological toxicity, those patients with \geq grade 3 toxicity have been highlighted in Figures 1D–F. Clearly, these responses hold true for the higher grades of toxicity, as patients with a TL less than the median had a 12.6-fold increased odds of suffering \geq grade 3 toxicity compared with having no toxicity (95% CI: 1.1–607, $P = 0.019$).

Multivariate analysis

Multivariate analysis was performed using independent variables of leukopenia, neutropenia, haematological (\geq grade 1) and mucositis for the Mayo daily schedule and diarrhoea for the weekly schedule (see Table 5). For each toxicity, a posttreatment and pretreatment model was generated using only those independent variables with a univariate association of $P < 0.25$ (as shown in Table 4). The posttreatment model included all of the pharmacokinetic variables for 5FU and excluded the uracil variables, whereas the predictive model utilised the pretreatment uracil parameters and excluded the posttreatment 5FU parameters (AUC, T_{1/2} and Cl).

For the Mayo daily schedule, all posttreatment models retained one pharmacokinetic variable for 5FU and were stronger predictors of haematological toxicities than their pretreatment counterparts, accounting for 32–56% of the variability. In contrast, the predictive models did not retain any of the pretreatment uracil parameters, but all contained TL and PLR (except neutropenia) and predicted 26–38% of the variability in toxicities. Only mucositis was better predicted by the pretreatment model (34% vs 33%).

For the weekly schedule, female gender remained the only significant predictor of diarrhoea in both pre- and posttreatment models.

Post-hoc analysis

As TL is often used to define biological aging, we chose to compare TL with chronological age in our patient cohorts. The results of our analysis did not show a correlation between age and PBMNC TL. We also conducted comparisons between PLR and NLR with albumin and BSA as SIRs are often related to overall nutritional status particularly malnutrition. The results did show a significant association between PLR and albumin ($R^2 = -0.439$, $P = 0.004$) and BSA ($R^2 = -0.518$, $P < 0.001$), but not between NLR and albumin or NLR and BSA. In order to further clarify the role of PLR in predicting clinical toxicity we also compared the relationship of PLR with the various 5FU PK variables and no significant association was observed.

DISCUSSION

In the present study a multifactorial approach was utilised to determine the predictive capability of numerous pharmacokinetic and pharmacodynamic parameters in response to 5FU chemotherapy in CRC patients undergoing either the Mayo Clinic or a weekly schedule of treatment. Although numerous studies have measured various baseline characteristics as a means of predicting 5FU toxicity (reviewed in Chua *et al*, 2011b), the present study identified 5FU PK, PBMNC TL and PLR as strong predictors of blood toxicity and mucositis.

Table 4 Univariate association between treatment-related toxicity vs PK and PD variables by 5FU treatment regimen

Variables	Treatment schedule									
	Mayo daily schedule								Weekly schedule	
	Leukopenia		Neutropenia		Haematological		Mucositis		Diarrhoea	
	n	r	n	r	n	r	n	r	n	r
<i>Pharmacokinetics (pretreatment)</i>										
Age	41	0.079	41	0.001	41	−0.058	42	−0.366*	31	0.032
Gender	41	0.157	41	0.148	41	0.137	42	0.003	31	0.553***
BSA	41	−0.397**	41	−0.368*	41	−0.253	42	−0.265	31	−0.263
U	38	0.017	38	−0.087	38	−0.086	39	0.138	29	0.098
UH ₂	37	−0.211	37	0.025	37	−0.094	38	0.025	29	0.054
UH ₂ /U	37	−0.140	37	0.086	37	0.011	38	−0.041	29	−0.062
AST	40	0.054	40	0.206	40	0.165	41	0.083	29	0.187
Albumin	41	−0.132	41	−0.062	41	−0.087	42	−0.170	29	−0.345
Bilirubin	41	−0.044	41	0.036	41	0.006	42	0.080	29	−0.314
Creatinine	41	−0.038	41	−0.064	41	−0.096	42	0.047	30	−0.171
<i>Pharmacokinetics (posttreatment)</i>										
5FU AUC	38	0.461**	38	0.448**	38	0.385*	39	0.162	28	0.151
5FU T _{1/2}	38	0.624***	38	0.496**	38	0.441**	39	0.256	28	0.209
5FU CL	38	−0.502***	38	−0.463**	38	−0.376*	39	−0.196	28	−0.231
5FUH ₂ AUC	38	0.012	38	0.089	38	−0.136	39	−0.203	28	0.149
5FU TOTAL	41	−0.268	41	−0.206	41	−0.123	42	−0.154	31	−0.200
<i>Pharmacodynamics (pretreatment)</i>										
WBC	41	−0.245	41	−0.281	41	−0.426**	42	−0.278	31	−0.153
Platelet	41	0.328*	41	0.275	41	0.165	42	0.155	31	−0.113
ANC	41	−0.109	41	−0.255	41	−0.406**	42	−0.137	31	−0.092
Lymphocyte	41	−0.332*	41	−0.107	41	−0.072	42	−0.290	31	−0.198
NLR	41	0.224	41	0.025	41	−0.057	42	0.148	31	0.062
PLR	41	0.429**	41	0.247	41	0.189	42	0.311*	31	0.073
TL	33	−0.468**	33	−0.438*	33	−0.501**	34	−0.330	29	0.076

Abbreviations: 5FU = 5-fluorouracil; ANC = absolute neutrophil count; AUC = area under the curve; BSA = body surface area; NLR = neutrophil to lymphocyte ratio; PD = pharmacodynamics; PK = pharmacokinetics; PLR = platelet lymphocyte ratio; TL = telomere length; WBC = white blood count. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

The observed clinical toxicity profiles were consistent with those reported in other patient cohorts with the Mayo schedule inducing significantly greater toxicity than the weekly schedule (Tsalic *et al*, 2003; Patel *et al*, 2004). The more aggressive Mayo therapy was characterised by a greater incidence of neutropenia, leukopenia and mucositis, whereas the principal toxicity in the less aggressive weekly schedule was diarrhoea. Although the weekly schedule produced less toxicity, the inclusion of this cohort still provided valid information in predicting for 5FU-induced toxicity. The study allowed us to compare the effect of low (weekly schedule) vs high toxicity (Mayo).

The results clearly show that 5FU pharmacokinetic parameters of AUC, T_{1/2} and CL predicted strongly for leukopenia, neutropenia and overall haematological toxicity, using univariate analysis in the Mayo cohort of patients. Subsequent multivariate analysis showed that 5FU AUC and T_{1/2} were the primary pharmacokinetic contributors to toxicity in this cohort. These observations compare favourably with other 5FU pharmacokinetic studies in CRC patients (Gamelin *et al*, 1996). In order to identify possible pretreatment factors that may substitute for these 5FU pharmacokinetic parameters, we examined uracil metabolism as a surrogate marker for 5FU metabolism. The results clearly showed a correlation between baseline concentrations of UH₂ and 5FUH₂, AUC providing the opportunity to assess actual enzymatic activity immediately before chemotherapy treatment. Indeed UH₂/U ratio has been used to predict patients with impaired DPD activity (Gamelin *et al*, 1999; Yang *et al*, 2011). According to these studies, a UH₂/U ratio of > 2.0 (Gamelin *et al*, 1999) or > 0.5 (Yang *et al*, 2011) would be indicative of normal DPD function. All of the

patients in our study cohort presented with a UH₂/U > 2.0 , thus none presented with DPD deficiency, indeed complete DPD depletion is a relatively rare event in the general population (Etienne *et al*, 1994). Not surprisingly, UH₂/U did not predict for clinical toxicity (Table 5); however, the strong relationship between UH₂/U and UH₂ with 5FUH₂ validates the ongoing use of UH₂/U as a surrogate marker for DPD activity as shown by other research groups.

Our results show for the first time that variability in TL may be a measure of end organ sensitivity to chemotherapy in humans. Although the actual biology underlying this mechanism remains to be determined, several lines of evidence suggest that the proliferative capacity of a cell, as measured by TL, determines its ability to effectively respond to environmental insults. Replicative strain on progenitor cell telomeres is observed in recipients of bone marrow transplants who have shorter blood cell telomeres compared with their donors (Wynn *et al*, 1998). We have previously shown that CD34+ progenitor cells with short TL took longer to repopulate the haematopoietic system than those with longer TL in cancer patients undergoing autologous bone marrow transplantation after high-dose chemotherapy (Lincz *et al*, 2004). Indeed, the relationship between TL in stem cell progenitor cells and bone marrow dysfunction has been well established (Ball *et al*, 1998; Du *et al*, 2009), and abnormally short TL have been associated with myeloproliferative disorders such as aplastic anaemia (Ball *et al*, 1998). It is perhaps not surprising that PBMNC TL could be used to predict haematological toxicity from 5FU. The link between PBMNC TL and the development of mucositis is less evident, but is likely to be dependent on




Figure 1 Association between 5FU-induced clinical toxicity and specific pre-treatment blood parameters in patients receiving the Mayo Schedule of chemotherapy. A smaller BSA ($P=0.01$) and an increase in PLR ($P=0.005$) strongly associates with the induction and severity of leukopenia (**A, B**). Induction and severity of mucositis strongly associates with younger patients ($P=0.017$) (**C**). Lower WBC ($P=0.006$) and lower ANC ($P=0.008$) strongly associates with induction of haematological toxicity (**D, E**). Short TL in PBMCs strongly associates ($P=0.003$) with induction of haematological toxicity (**F**). Haematological toxicity is defined as grade 1 or greater leukopenia and/or neutropenia (shaded circles represent grades 3 and 4). The solid bar represents the median value.

production of blood cells for adequate wound healing. Indeed, this process is severely compromised via a delay in reepithelialisation in telomerase-deficient mice presenting with severely short TL (Rudolph *et al*, 1999). Moreover, in an aging cohort of telomerase-deficient mice (mTR $^{-/-}$), TL shortening was associated with reduced capacity to respond to stresses such as wound healing and 5FU-induced haematopoietic ablation (Rudolph *et al*, 1999). However, we cannot exclude the possibility that the mucosal cells may also have had short telomeres, increasing their susceptibility to the chemotherapy insult.

It is generally the case that younger people possess longer telomeres than older people (Hastie *et al*, 1990; Lindsey *et al*, 1991; Slagboom *et al*, 1994; Vaziri *et al*, 1994; Ball *et al*, 1998; Frenck *et al*, 1998; Wynn *et al*, 1998); however, it is now evident that telomere attrition is a combination of continued cell replication and oxidative damage (Blackburn, 2005; Epel, 2009). Thus, lifestyle

and oxidative status significantly contribute to telomere dynamics, as evidenced by the lack of association between TL and age in our study cohort. This is further substantiated by the existence of both age and TL in the model of mucositis, indicating that the two measurements are independent and refer to different biological processes. Indeed, younger patients in our cohort were most likely to present with mucositis. Previous studies looking at age and mucositis risk have shown mixed results, with the very young and the very old both at a greater risk (Barasch and Peterson, 2003; Keefe, 2006). The increased turnover of the mucosal lining of younger patients may be the underlying cause of their sensitivity (Barasch and Peterson, 2003), whereas the cause in the very elderly is not known.

Toxicity was also strongly predicted by PLR, a known marker of SIR. This and other markers of SIR such as C-reactive protein (CRP), Glasgow Prognostic Score (combining albumin and CRP)

Table 5 Multivariate analysis of toxicity vs independent variables in CRC patients receiving 5FU treatment. The posttreatment model utilised 5FU PK variables while the predictive model utilised U variables.

Dependent variable	Model	Stepwise regression			Independent variables		
		<i>n</i>	Adjusted <i>R</i> ²	<i>P</i>	<i>B</i>	<i>β</i>	<i>P</i>
Mayo daily schedule							
Leukopenia	Posttreatment	32	0.56	<0.00001	Intercept	8.03	0.015
					TL	− 0.208	0.125
					5FU T _{1/2}	0.490	0.001
					PLR	0.363	0.007
	Predictive	32	0.36	<0.0006	Intercept	9.38	0.017
					TL	− 0.381	0.016
					PLR	0.415	0.009
Neutropenia	Posttreatment	32	0.32	<0.003	Intercept	− 2.21	0.340
					ANC	− 0.299	0.082
					5FU AUC	0.439	0.007
					PLR	0.405	0.019
	Predictive	32	0.26	<0.009	Intercept	20.5	0.0008
					BSA	− 0.354	0.036
					TL	− 0.342	0.042
					ANC	− 0.225	0.174
Haematological (≥ grade 1)	Posttreatment	33	0.42	<0.0006	Intercept	104	0.0000
					TL	− 0.315	0.037
					ANC	− 0.408	0.013
					5FU AUC	0.247	0.094
					PLR	0.362	0.022
	Predictive	33	0.38	<0.0006	Intercept	106	0.0000
					TL	− 0.378	0.014
					ANC	− 0.454	0.007
					PLR	0.367	0.025
Mucositis	Posttreatment	34	0.33	<0.002	Intercept	5.5	0.001
					Age	− 0.407	0.009
					FU _{H2} AUC	− 0.236	0.115
					PLR	0.410	0.008
	Predictive	34	0.34	<0.001	Intercept	9.5	0.008
					Age	− 0.428	0.005
					TL	− 0.251	0.089
					PLR	0.383	0.012
Weekly Schedule							
Diarrhoea	Posttreatment	26	0.20	<0.013	Intercept	− 80	0.014
					Gender	0.479	0.013
	Predictive	29	0.24	<0.004	Intercept	− 85	0.004
					Gender	0.516	0.004

Abbreviations: 5FU = 5-fluorouracil; ANC = absolute neutrophil count; AUC = area under the curve; B = intercept regression coefficient; β = standardised regression coefficient; BSA = body surface area; FU_{H2} = dihydrofluorouracil; PK = pharmacokinetics; PLR = platelet lymphocyte ratio; TL = telomere length; U = uracil; UH₂ = dihydrouracil.

and NLR (Chua *et al*, 2011a) have shown prognostic significance for various malignancies, including CRC, when employed in the preoperative setting. However, only one other study has examined the relationship of PLR to chemotherapy-induced toxicity (Arrieta *et al*, 2010). Generally, a PLR value of ≥ 150 and a NLR value of ≥ 5 represent a SIR (Arrieta *et al*, 2010; Chua *et al*, 2011a). In our cohort of patients 18 of 41 (44%) had a PLR ≥ 150 , of which 12 presented with grade 1 or higher leukopenia (Figure 1), whereas NLR did not predict for toxicity; indeed only 5 of 41 (12%) patients had a NLR ≥ 5 . In two other CRC cohorts the proportion of patients with an NLR > 5 was reported to be 29% and 31% (Chua *et al*, 2011a) and predicted for PFS and OS; however, these cohorts represented metastatic disease, suggesting that the incidence of NLR > 5 may increase with disease progression. Unfortunately, PLR was not studied in these advanced CRC studies, and the lack of follow-up survival data in the current study make it impossible to draw any conclusions. The underlying cause and development of SIR in oncology patients is unclear. Some suggestions included tumour hypoxia-necrosis and local tissue damage causing

disturbances in neuroendocrine metabolism, interleukine synthesis and acute phase protein production. However, the present cohort of patients was assessed in the adjuvant setting, precluding tumour-associated effects. The link between SIR and clinical toxicity is also unclear. Increased toxicity may be caused by a reduction in chemotherapy metabolism which would raise plasma 5FU levels. Indeed, acute phase reactants produced during SIR are known to alter the liver function and have been associated with increased plasma albumin and BSA (Arrieta *et al*, 2010). Although a similar phenomenon was observed in our patient cohort, there was no association between PLR and 5FU PK variables, suggesting that any decrease in liver function was not sufficient to impact on 5FU metabolism or plasma levels.

In conclusion, we have shown that measures of U metabolism can predict for 5FU metabolism, and that peripheral blood mononuclear cell TL and PLR were identified as strong predictors of 5FU-induced toxicity. Although the results provide clear evidence to suggest that preclinical assessment of TL and simple blood cell analysis should be included in standard pretreatment

blood screening in CRC patients preparing for chemotherapy, it is also important to validate these findings in other CRC chemotherapy regimens. Such screening would identify those patients most likely to experience haematological toxicity and mucositis; providing crucial information for optimising patient care. Indeed many elderly patients forego chemotherapy and many clinicians withhold chemotherapy on the belief that age predicts for poor clinical outcome and increased toxicity. Our study refutes this and

provides a simple means to determine patient suitability for chemotherapy.

ACKNOWLEDGEMENTS

We are grateful for financial support from the Calvary Mater Newcastle Hospital and the University of Newcastle, NSW Australia.

REFERENCES

- Ackland SP, Garg MB, Dunstan RH (1997) Simultaneous determination of dihydroflurouracil and 5-fluorouracil in plasma by high-performance liquid chromatography. *Anal Biochem* **246**: 79–85
- Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, Serna-Thomé M, Flores-Estrada D, Diaz-Romero C, Rodríguez CM, Martínez L, Sánchez-Lara K (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. *BMC Cancer* **10**: 50
- Ball SE, Gibson FM, Rizzo S, Toozé JA, Marsh JCW, Gordon-Smith EC (1998) Progressive telomere shortening in aplastic anemia. *Blood* **91**: 3582–3592
- Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. *Oral Oncol* **39**: 91–100
- Blackburn EH (2005) Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. *FEBS Lett* **579**: 859–862
- Chua W, Charles KA, Baracos VE, Clarke SJ (2011a) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. *Br J Cancer* **104**: 1288–1295
- Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ (2011b) Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. *Crit Rev Oncol Hematol* **79**: 224–250
- Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B (2006) A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. *Ther Drug Monit* **28**: 678–685
- Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. *J Clin Invest* **81**: 47–51
- Du H-Y, Pumbo E, Ivanovich J, An P, Maziarz RT, Reiss UM, Chirnomas D, Shimamura A, Vlachos A, Lipton JM, Goyal RK, Goldman F, Wilson DB, Mason PJ, Bessler M (2009) *TERC* and *TERT* gene mutations in patients with bone marrow failure and the significance of telomere length measurements. *Blood* **113**: 309–316
- Epel ES (2009) Psychological and metabolic stress: a recipe for accelerated cellular aging? *Hormones* **8**: 7–22
- Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. *J Clin Oncol* **12**: 2248–2253
- Frenck Jr RW, Blackburn EH, Shannon KM (1998) The rate of telomere sequence loss in human leukocytes varies with age. *PNAS* **95**: 5607–5610
- Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. *J Clin Oncol* **17**: 1105–1105
- Gamelin E, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG (1996) Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. *Cancer* **77**: 441–451
- Garg MB, Sevester JC, Sakoff JA, Ackland SP (2002) Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. *J Chromatogr B* **774**: 223–230
- Goldberg JA, Kerr DJ, Willmott N, McKillop JH, McArdle CS (1988) Pharmacokinetics and pharmacodynamics of locoregional 5-fluorouracil (5FU) in advanced colorectal liver metastases. *Br J Cancer* **57**: 186–189
- Gurney HP, Ackland SP, Gebiski V, Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. *J Clin Oncol* **16**: 2299–2304
- Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, Bononi A, Crepaldi G, Menon D, Stievano L, Toso S, Pasini F, Ferrazzi E, Padriani R (2009) Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. *Br J Cancer* **100**: 1549–1557
- Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC (1990) Telomere reduction in human colorectal carcinoma and with ageing. *Nature* **346**: 866–868
- Keefe DMK (2006) Mucositis management in patients with cancer. *Support Cancer Ther* **3**: 154–157
- Lincz LF, Scorgie FE, Sakoff JA, Fagan KA, Ackland SP, Enno A (2004) Telomere length predicts neutrophil recovery in the absence of G-CSF after autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* **34**: 439–445
- Lindsey J, McGill NI, Lindsey LA, Green DK, Cooke HJ (1991) In vivo loss of telomeric repeats with age in humans. *Mutat Res* **256**: 45–48
- Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. *Cancer Res* **53**: 5433–5438
- Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, Demard F (1994) Relationship between fluorouracil systemic exposure and tumour response and patient survival. *J Clin Oncol* **12**: 1291–1295
- Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* **16**(3): 1215
- Patel K, Anthoney DA, Crellin AM, Sebag-Montefiore D, Messruther J, Seymour MT (2004) Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. *Ann Oncol* **15**: 568–573
- Rhyu MS (1995) Telomeres, Telomerase, and Immortality. *J Natl Cancer Inst* **87**: 884–894
- Rudolph KL, Chang S, Lee H-W, Blasco M, Gottlieb GJ, Greider C, DePinho RA (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. *Cell* **96**: 701–712
- Sakoff JA, De Waal E, Garg MB, Denham J, Scorgie FE, Enno A, Lincz LF, Ackland SP (2002) Telomere length in haemopoietic stem cells can be determined from that of mononuclear blood cells or whole blood. *Leuk Lymphoma* **43**: 2017–2020
- Slagboom PE, Droog S, Boomsma DI (1994) Genetic determination of telomere size in humans: a twin study of three age groups. *Am J Hum Genet* **55**: 866–869
- Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP, Goldman ID (1982) Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. *J Biol Chem* **257**: 8171–8176
- Tsalić M, Bar-Sela G, Beny A, Visel B, Haim N (2003) Severe toxicity related to the 5-fluorouracil/leucovorin combination (The Mayo Clinic Regimen). *Am J Clin Oncol* **26**: 103–106
- Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, van, Lenthe H, De Abreu RA, Smeitink JA, Kayserili H, Apak MY, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer WJ, Beemer FA, Duran M, Niezen-Koning KE, Smit GP, Jakobs C, Smit LM, van Gennip AH (1999) Genotype and phenotype in patients

- with dihydropyrimidine dehydrogenase deficiency. [Review] [72 refs]. *Hum Genet* **104**: 1–9
- Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM (1994) Evidence for a mitotic clock in human hematopoietic stem-cells - loss of telomeric DNA with age. *PNAS* **91**: 9857–9860
- Vokes EE, Mick R, Kies MS, Dolan E, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ (1996) Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. *J Clin Oncol* **14**: 1663–1671
- Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, Testa NG (1998) Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. *Lancet* **351**: 178–181
- Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-L D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens R-M, Chefrour M, Favre R, Duffaund F, Seitz J-F, Zanaret M, Lacarelle B, Mercier C (2011) DPD-based adaptive dosing of 5FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. *Cancer Chemother Pharmacol* **67**: 49–56

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.